Recent developments in humanized MAbs for immunotherapy: a personal tribute to Dr. Martin Lockwood.
Hale
G
G
Sir William Dunn School of Pathology, University of Oxford, UK.
D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000266:history* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000266:history / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000266:history / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000266:history / Q000627:therapeutic use; D049673:History, 20th Century; D006801:Humans; D007167:Immunotherapy / Q000266:history*; D014657:Vasculitis / Q000188:drug therapy / Q000266:history
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D000074323:Alemtuzumab